Keyphrases
Cyclic GMP
100%
Nitric Oxide
100%
Receptor-mediated
100%
Neuronal Cells
100%
Cannabinoid Receptor 1 (CB1R)
100%
Guanylate Cyclase
100%
CB1 Receptor
37%
N18TG2
37%
Pertussis Toxin
25%
Rimonabant
25%
Cannabinoid Agonists
25%
GMP Production
25%
Cytosolic Proteins
12%
Drug Treatment
12%
Long-term Treatment
12%
Membrane Fraction
12%
Cyclic Adenosine Monophosphate (cAMP)
12%
Downstream Effects
12%
Neuroblastoma Cells
12%
Cannabinoids
12%
Endocannabinoids
12%
Intracellular Translocation
12%
PKG2
12%
CB1 Antagonist
12%
SR141716
12%
CB2 Cannabinoid Receptor
12%
CP55940
12%
WIN55,212-2
12%
Inactivator
12%
Pharmacology, Toxicology and Pharmaceutical Science
Nitric Oxide
100%
Cyclic GMP
100%
Guanylate Cyclase
100%
Cannabinoid Receptor
100%
Rimonabant
37%
Cannabinoid
37%
Cannabinoid 1 Receptor
37%
Pertussis Toxin
25%
Neuroblastoma
12%
Pharmacotherapy
12%
Cyclic AMP
12%
Endocannabinoid
12%
Cannabinoid 2 Receptor
12%
1h 1,2,4 oxadiazolo[4,3 A]quinoxalin 1 One
12%
4 (1,1 Dimethylheptyl) 1',2',3',4',5',6' Hexahydro 2,3' Dihydroxy 6' (3 Hydroxypropyl)biphenyl
12%
Neuroscience
Nitric Oxide
100%
Cannabinoid Receptor
100%
Cyclic Guanosine Monophosphate
100%
Guanylate Cyclase
100%
Cannabinoid
37%
Cannabinoid 1 Receptor
37%
Pertussis Toxin
25%
Agonist
25%
Neuroblastoma
12%
Cyclic Adenosine Monophosphate
12%
Endocannabinoid
12%